Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences
Eledon Pharmaceuticals, Inc. (ELDN)
Company Research
Source: GlobeNewswire
IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences: Event:LifeSci Partners Corporate Access Event (January 5-7, 2022)Format:1x1 Meetings To register for the LifeSci Partners Corporate Access Event, please use the following link: here. Event:H.C. Wainwright BIOCNNECT Virtual Conference (January 10-13, 2022)Format:Available on Demand Presentation for registered attendees via the H.C. Wainwright site and 1x1 Meetings If you are interested in arranging a one-on-one meeting request for the H.C. Wainwright BIOCNNECT Virtual Conference, please contact your H.C. Wainwright representative, or contact Corey Davis
Show less
Read more
Impact Snapshot
Event Time:
ELDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELDN alerts
High impacting Eledon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ELDN
News
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsGlobeNewswire
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionGlobeNewswire
- Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
ELDN
Earnings
- 11/9/23 - Beat
ELDN
Analyst Actions
- 3/22/24 - HC Wainwright
ELDN
Sec Filings
- 3/28/24 - Form 10-K
- 3/28/24 - Form 8-K
- 2/14/24 - Form SC
- ELDN's page on the SEC website